Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer’s Disease
Apolipoprotein E4 (ApoE4) is the most recognized genetic risk factor for late-onset Alzheimer’s disease (LOAD), whereas ApoE2 reduces the risk for LOAD. The underlying mechanisms are unclear but may include effects on brain energy metabolism. Here, we used neuro-2a (N2a) cells that stably express hu...
Main Authors: | Xin Zhang, Long Wu, Russell H. Swerdlow, Liqin Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/3/410 |
Similar Items
-
ApoE4: an emerging therapeutic target for Alzheimer’s disease
by: Mirna Safieh, et al.
Published: (2019-03-01) -
Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model
by: Tien-Phat V. Huynh, et al.
Published: (2019-10-01) -
APOE and Alzheimer’s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction
by: Jason A. Brandon, et al.
Published: (2018-06-01) -
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
by: Sheina Emrani, et al.
Published: (2020-11-01) -
The Endosomal–Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo
by: Tal Nuriel, et al.
Published: (2017-12-01)